KR20220132552A - 알파-히드록실화 지방산의 대사산물, 이의 의학적 용도 및 바이오마커로서의 용도 - Google Patents

알파-히드록실화 지방산의 대사산물, 이의 의학적 용도 및 바이오마커로서의 용도 Download PDF

Info

Publication number
KR20220132552A
KR20220132552A KR1020227027634A KR20227027634A KR20220132552A KR 20220132552 A KR20220132552 A KR 20220132552A KR 1020227027634 A KR1020227027634 A KR 1020227027634A KR 20227027634 A KR20227027634 A KR 20227027634A KR 20220132552 A KR20220132552 A KR 20220132552A
Authority
KR
South Korea
Prior art keywords
compound
formula
integer
acceptable salt
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227027634A
Other languages
English (en)
Korean (ko)
Inventor
파블로 비센테 에스크리바 루이즈
마누엘 토레스 카날레호
자비에르 부스케츠 자베트
빅토리아 라도 카넬라스
파우라 페르난데스 가르시아
카탈리나 아나 로셀로 카스티요
세바스티아 파렛츠 바리오스
로베르토 베테타 고벨
에밀스 카노 우레고
라우라 아르보나 곤잘레스
라켈 로드리게즈 로르카
후안 카봇 바우자
마크 밀라레스 피자
Original Assignee
유니버시다드 데 레스 일레스 발레아르스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES202030070A external-priority patent/ES2846824B2/es
Priority claimed from ES202031155A external-priority patent/ES2911474B2/es
Application filed by 유니버시다드 데 레스 일레스 발레아르스 filed Critical 유니버시다드 데 레스 일레스 발레아르스
Publication of KR20220132552A publication Critical patent/KR20220132552A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227027634A 2020-01-29 2021-01-28 알파-히드록실화 지방산의 대사산물, 이의 의학적 용도 및 바이오마커로서의 용도 Pending KR20220132552A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
ESP202030070 2020-01-29
ES202030070A ES2846824B2 (es) 2020-01-29 2020-01-29 Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
EP20382145.9 2020-02-28
EP20382145 2020-02-28
ESP202031155 2020-11-17
ES202031155A ES2911474B2 (es) 2020-11-17 2020-11-17 Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
PCT/ES2021/070068 WO2021152201A2 (es) 2020-01-29 2021-01-28 Metabolitos de ácidos grasos alfa-hidroxilados, usos médicos de los mismos y uso como biomarcadores

Publications (1)

Publication Number Publication Date
KR20220132552A true KR20220132552A (ko) 2022-09-30

Family

ID=77078835

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227027634A Pending KR20220132552A (ko) 2020-01-29 2021-01-28 알파-히드록실화 지방산의 대사산물, 이의 의학적 용도 및 바이오마커로서의 용도

Country Status (12)

Country Link
US (1) US20230097753A1 (enExample)
EP (1) EP4098649A4 (enExample)
JP (1) JP7736313B2 (enExample)
KR (1) KR20220132552A (enExample)
CN (1) CN115052852A (enExample)
AU (2) AU2021212330A1 (enExample)
BR (1) BR112022015172A2 (enExample)
CA (2) CA3233141A1 (enExample)
CL (1) CL2022001985A1 (enExample)
IL (1) IL295120A (enExample)
MX (1) MX2022009035A (enExample)
WO (1) WO2021152201A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
ES2982396A1 (es) * 2023-03-14 2024-10-15 Veritas Therapeutics S L 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195296B (de) * 1958-06-28 1965-06-24 Dr Gernot Grimmer Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der cis-9-Pentadecensaeure und der cis-9-Heptadecensaeure
DE1147221B (de) * 1958-06-28 1963-04-18 Dr Rer Nat Gernot Grimmer Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der Pentadecen- und Heptadecensaeuren
GB1156465A (en) * 1967-02-16 1969-06-25 Unilever Ltd Prostaglandins
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
DE102007055344A1 (de) * 2007-11-19 2009-05-20 K. D. Pharma Bexbach Gmbh Neue Verwendung von Omega-3-Fettsäure(n)
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
KR20120065276A (ko) * 2009-05-29 2012-06-20 뉴 챕터, 인코포레이티드. 지질 조성을 조정하기 위한 조성물 및 방법
CN102276444B (zh) * 2011-05-04 2013-10-09 厦门大学 脂肪酸类化合物及其制备方法与应用
ES2401629B1 (es) 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2014113584A1 (en) * 2013-01-16 2014-07-24 Rhode Island Hospital Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
US20150173410A1 (en) * 2013-12-19 2015-06-25 Change Cola, Inc. Beverage comprising omega fatty acid
JP2016222590A (ja) * 2015-05-29 2016-12-28 国立大学法人東京海洋大学 脂肪酸の同位体標識化合物の製造方法およびその方法により得られた脂肪酸の同位体標識化合物、ならびに診断薬
WO2019241728A1 (en) * 2018-06-15 2019-12-19 Youhealth Biotech, Limited Composition and methods for modulation of elovl2

Also Published As

Publication number Publication date
AU2023248158B2 (en) 2025-11-27
IL295120A (en) 2022-09-01
AU2021212330A1 (en) 2022-09-22
EP4098649A4 (en) 2024-04-17
BR112022015172A2 (pt) 2022-10-11
AU2023248158A1 (en) 2023-11-02
CL2022001985A1 (es) 2023-02-03
WO2021152201A2 (es) 2021-08-05
CN115052852A (zh) 2022-09-13
WO2021152201A3 (es) 2021-09-23
MX2022009035A (es) 2022-08-11
JP7736313B2 (ja) 2025-09-09
US20230097753A1 (en) 2023-03-30
CA3166307C (en) 2024-05-21
CA3233141A1 (en) 2021-08-05
CA3166307A1 (en) 2021-08-05
EP4098649A2 (en) 2022-12-07
JP2023518640A (ja) 2023-05-08

Similar Documents

Publication Publication Date Title
AU2023248158B2 (en) Alpha-Hydroxylated Fatty-Acid Metabolites, Medical Uses of Same and Use as Biomarkers
AU2019222911B2 (en) Berberine salts, ursodeoxycholic salts and combinations, methods of prepration and application thereof
JP6506206B2 (ja) Ｐｕｆａ誘導体による酸化ストレス障害の緩和
Wen et al. DHA-PC and DHA-PS improved Aβ1–40 induced cognitive deficiency uncoupled with an increase in brain DHA in rats
KR101833772B1 (ko) 고도불포화 지방산 유도체의 의약으로서 용도
JP7132630B2 (ja) 同位体修飾成分及びその治療上の使用
JP2021121614A (ja) 神経変性障害および筋疾患に関与するｐｕｆａ
JP7025212B2 (ja) 炎症性、変性及び神経変性疾患の治療のための化合物、組成物及び方法
JP2022513933A (ja) 有機化合物
US20160045468A1 (en) Novel therapeutic target for the treatment of cancers and related therapies and methods
KR20250035567A (ko) 안정된 실로신 염, 에스테르 및 접합체의 제조 및 이의 용도
WO2010007788A1 (ja) グリチルレチン酸誘導体及びその利用
RU2841595C1 (ru) Метаболиты альфа-гидроксилированных жирных кислот, их медицинские применения и применение в качестве биомаркеров
EP3209637B1 (en) 2-hydroxy-triacylglycerol compounds for use in treating disease
HK40081413A (en) Alpha-hydroxylated fatty-acid metabolites, medical uses of same and use as biomarkers
US20230093594A1 (en) Pantethenoylcysteine derivatives and uses thereof
JP7589972B2 (ja) 小胞型ヌクレオチドトランスポーター阻害剤
ES2911474B2 (es) Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
JP2024523589A (ja) アンジオテンシン及びその類似体の投与によるシナプス形成の誘導方法
JP2023502791A (ja) 大環状パンテテイン誘導体およびその用途
JP7280470B2 (ja) 特定アミノ酸またはアミノ酸様物質による低酸素応答制御
JP2023092723A (ja) 脳機能改善剤
WO2020090570A1 (ja) 光障害低減剤
HK40013804A (en) Alleviating oxidative stress disorders with pufa derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902